The study purpose is to demonstrate that ventricular tachycardia (VT) ablation using the Niobe™ ES system results in superior outcomes compared to a manual approach in subjects with ischemic scar VT in a low ejection fraction population.
This study is a randomized, single-blind, prospective, multi-center post market evaluation. Subjects will be screened for study eligibility and asked to complete written informed consent prior to any study specific testing assessments. After completing written informed consent, a total of 386 subjects will be randomized on a 1:1 basis to receive VT ablation treatment using either the Niobe ES or standard manual catheter ablation treatment using commercially available products. This will be the largest randomized VT study comparing outcomes from RMN to manually guided catheter ablation procedures. Subjects will be randomized according to a computer-generated randomization scheme. Randomization will be blocked at the study site level and subjects will be blinded to group assignment. Since quality of life measurements will be collected during follow-up, this study is single-blinded in order to mitigate patient bias. Clinical evaluations will not be masked to the treating physician.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
182
elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.
elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.
Florida Hospital
Orlando, Florida, United States
Augusta University
Augusta, Georgia, United States
University of Chicago Medical Center
freedom from any VT in the overall cohort
Time frame: 12 months
acute success of procedure
non-inducibility of clinical VT and/or other monomorphic VT using typical stimulation protocol for induction
Time frame: at end of procedure (immediate)
freedom from VT in large scar subpopulation
Time frame: 12 months
major adverse events
death, cardiac tamponade, stroke, bleeding requiring surgical intervention, progressive heart failure related to VT/VF recurrence
Time frame: 48 hours post-procedure
mortality rate
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Chicago, Illinois, United States
Advocate Christ Medical Center
Oak Lawn, Illinois, United States
The University of Kansas Medical Center
Kansas City, Kansas, United States
Weill Cornell Medical
New York, New York, United States
Texas Cardiac Arrhythmia Research Foundation
Austin, Texas, United States
Intermountain Heart Institute
Murray, Utah, United States
Westmead Hospital
Westmead, New South Wales, Australia
AZ Sint-Jan
Bruges, West Flanders, Belgium
...and 6 more locations